New cancer drug HY0001a enters human trials for advanced solid tumors
NCT ID NCT07069062
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called HY0001a in 261 people with advanced solid tumors who have no other treatment options. The study aims to find a safe dose and see if the drug can shrink tumors. It is currently recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HY0001a
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early phase 1/2 trial with only 261 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100143, China
Contact Phone: •••-•••-•••• Email: •••••@•••••